Research Article
Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma
Table 2
Combination of ribociclib and IFN-α is synergistic in inhibiting the proliferation of some RCC cell lines.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||